Zydus Lifesciences Ltd on Monday said it has received final approval from the US health regulator to manufacture and market its generic version of Azithromycin tablets used in the treatment of certain bacterial infections. The approval by the US Food and Drug Administration (USFDA) is for manufacturing and marketing of Azithromycin tablets 500 mg strength, Zydus Lifesciences said in a regulatory filing.